BR112014004782A2 - formulações adjuvantes de antígenos de staphylococcus aureus - Google Patents

formulações adjuvantes de antígenos de staphylococcus aureus

Info

Publication number
BR112014004782A2
BR112014004782A2 BR112014004782A BR112014004782A BR112014004782A2 BR 112014004782 A2 BR112014004782 A2 BR 112014004782A2 BR 112014004782 A BR112014004782 A BR 112014004782A BR 112014004782 A BR112014004782 A BR 112014004782A BR 112014004782 A2 BR112014004782 A2 BR 112014004782A2
Authority
BR
Brazil
Prior art keywords
staphylococcus aureus
adjuvant formulations
aureus antigens
antigens
adjuvant
Prior art date
Application number
BR112014004782A
Other languages
English (en)
Portuguese (pt)
Inventor
Baudner Barbara
Bagnoli Fabio
Bufali Simone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014004782A2 publication Critical patent/BR112014004782A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112014004782A 2011-09-01 2012-08-31 formulações adjuvantes de antígenos de staphylococcus aureus BR112014004782A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US201261607999P 2012-03-07 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
BR112014004782A2 true BR112014004782A2 (pt) 2017-03-21

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004782A BR112014004782A2 (pt) 2011-09-01 2012-08-31 formulações adjuvantes de antígenos de staphylococcus aureus

Country Status (14)

Country Link
US (1) US20140363461A1 (https=)
EP (1) EP2763695A1 (https=)
JP (1) JP2014525429A (https=)
KR (1) KR20140066212A (https=)
CN (1) CN104093418A (https=)
AU (1) AU2012300765A1 (https=)
BR (1) BR112014004782A2 (https=)
CA (1) CA2847204A1 (https=)
IL (1) IL231104A0 (https=)
IN (1) IN2014CN02152A (https=)
MX (1) MX2014002363A (https=)
RU (1) RU2014112343A (https=)
SG (1) SG11201400210RA (https=)
WO (1) WO2013030378A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2414384B2 (en) * 2009-04-03 2023-05-03 Momenta Pharmaceuticals, Inc. Control of copolymer compositions
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
SG11201400210RA (en) * 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
MX346678B (es) * 2012-03-07 2017-03-29 Novartis Ag Sales de arginina utiles inmunologicamente.
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
JP2015532594A (ja) * 2012-08-31 2015-11-12 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
HUE044211T2 (hu) * 2012-08-31 2019-10-28 Glaxosmithkline Biologicals Sa Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus
BE1022857A1 (fr) * 2014-03-26 2016-09-27 Glaxosmithkline Biologicals Sa Immunisation contre staphylococcus aureus
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
KR102726248B1 (ko) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3485094D1 (de) 1983-01-25 1991-10-31 Ciba Geigy Ag Neue peptidderivate.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE157882T1 (de) 1993-03-23 1997-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
ATE457737T1 (de) 2003-07-24 2010-03-15 Merck & Co Inc Polypeptide zur induktion einer schützenden immunantwort gegen staphylococcus aureus
CN1980692A (zh) 2003-07-24 2007-06-13 麦克公司 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
AU2005214061B2 (en) 2004-02-18 2010-02-04 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939200A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
JPWO2007034881A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
WO2007093901A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as tlr7 modulators
EP2043690A1 (en) 2006-06-12 2009-04-08 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
EP2041135A4 (en) 2006-07-05 2010-12-01 Astrazeneca Ab As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK
EP2038290B1 (en) 2006-07-07 2013-09-04 Gilead Sciences, Inc. Modulators of toll-like receptor 7
CA2667788A1 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
US20100120799A1 (en) 2007-02-19 2010-05-13 Smithkline Beecham Corporation Purine derivatives as immunomodulators
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
KR20100016289A (ko) 2007-05-08 2010-02-12 아스트라제네카 아베 면역-조정 특성의 이미다조퀴놀린
CA2707030A1 (en) 2007-08-03 2009-02-12 Pfizer Limited Imidazopyridinones
EP2185190B1 (en) 2007-08-31 2015-06-24 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
ES2667054T3 (es) 2008-03-24 2018-05-09 Biontech Ag Nuevas imidazoquinolinas sustituidas
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
ES2467108T3 (es) 2008-12-09 2014-06-11 Gilead Sciences, Inc. Moduladores de receptores tipo toll
MX2011010735A (es) * 2009-04-14 2012-01-25 Novartis Ag Composiciones para inmunizacion contra staphylococcus aureus.
HUE036372T2 (hu) * 2009-06-22 2018-07-30 Wyeth Llc Staphylococcus aureus antigének immunogén készítményei
ES2625979T3 (es) 2009-07-16 2017-07-21 Glaxosmithkline Biologicals S.A. Tratamiento de infecciones
GB0913681D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) * 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
ES2458355T3 (es) 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
WO2012117377A1 (en) * 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
SG11201400210RA (en) * 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
JP2015510872A (ja) * 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
MX372965B (es) * 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
CN104582723A (zh) * 2012-08-31 2015-04-29 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
JP2015532594A (ja) * 2012-08-31 2015-11-12 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
HUE044211T2 (hu) * 2012-08-31 2019-10-28 Glaxosmithkline Biologicals Sa Staphylococcus aureus elleni immunizálásra szolgáló, stabilizált fehérjék
US20150202277A1 (en) * 2012-08-31 2015-07-23 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
US9526776B2 (en) * 2012-09-06 2016-12-27 Glaxosmithkline Biologicals Sa Combination vaccines with serogroup B meningococcus and D/T/P
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
JP6411378B2 (ja) * 2013-02-01 2018-10-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
BE1022857A1 (fr) * 2014-03-26 2016-09-27 Glaxosmithkline Biologicals Sa Immunisation contre staphylococcus aureus
BE1022875B1 (fr) * 2014-03-26 2016-09-30 Glaxosmithkline Biologicals S.A. Compositions pour une immunisation contre staphylococcus aureus

Also Published As

Publication number Publication date
CA2847204A1 (en) 2013-03-07
IL231104A0 (en) 2014-04-30
AU2012300765A1 (en) 2014-03-13
RU2014112343A (ru) 2015-10-10
KR20140066212A (ko) 2014-05-30
IN2014CN02152A (https=) 2015-09-04
SG11201400210RA (en) 2014-03-28
JP2014525429A (ja) 2014-09-29
CN104093418A (zh) 2014-10-08
WO2013030378A1 (en) 2013-03-07
US20140363461A1 (en) 2014-12-11
MX2014002363A (es) 2014-04-14
EP2763695A1 (en) 2014-08-13

Similar Documents

Publication Publication Date Title
BR112014004782A2 (pt) formulações adjuvantes de antígenos de staphylococcus aureus
BR112013016153A2 (pt) composições imunogênicas estáveis de antígenos de staphylococcus aureus
CO6801637A2 (es) Formulaciones de anticuerpos
EP2747556A4 (en) pyrethroid formulations
DK3091029T5 (da) Anti-IL13-antistofformuleringer
FR2970871B1 (fr) Mouche-bebe
DK3117837T3 (da) Antistofformuleringer
BR112012030950A2 (pt) formulações de vacina
EP2725900A4 (en) ANTIMICROBIAL COMPOSITION
CO6950492A2 (es) Composiciones plaguicidas estables
IL217084A0 (en) Immunogenic compositions of staphylococcus aureus antigens
HRP20160887T1 (hr) Formulacije testosterona
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada
BR112014004779A2 (pt) formulações de derivados de decitabina
CO6870048A2 (es) Formulación herbicida mejorada
HRP20171889T1 (hr) Formulacije kombinacije darunavira
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
SMT201600380B (it) Formulazioni di darunavir
CO7020931A2 (es) Composiciones herbicidas sólidas mejoradas con adyuvante incorporado
IL230038B (en) Herbicidal composition
CO6791617A2 (es) Combinaciones de compuestos activos
EP2931042A4 (en) ANTHRACYCLINFORMULIERUNGEN
DK3251507T3 (da) Forbedrede insekticidformuleringer
CO6821942A2 (es) Combinaciones de compuestos activos
EP2593134A4 (en) PROTECTION BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2412

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]